These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10076919)

  • 1. Cardiac and vascular remodelling: effect of antihypertensive agents.
    Mallion JM; Baguet JP; Siche JP; Tremel F; De Gaudemaris R
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S35-41; discussion S49-50. PubMed ID: 10076919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?
    Fleischmann EH; Schmieder RE
    Curr Cardiol Rep; 2002 Nov; 4(6):474-8. PubMed ID: 12379166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in left ventricular geometry during antihypertensive treatment.
    Salvetti M; Paini A; Bertacchini F; Stassaldi D; Aggiusti C; Agabiti Rosei C; Bassetti D; Agabiti-Rosei E; Muiesan ML
    Pharmacol Res; 2018 Aug; 134():193-199. PubMed ID: 29959031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antihypertensive agents on the left ventricle: clinical implications.
    Díez J; González A; López B; Ravassa S; Fortuño MA
    Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure.
    Derosa G; Maffioli P
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):719-28. PubMed ID: 23750681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice.
    Ye Y; Gong H; Wang X; Wu J; Wang S; Yuan J; Yin P; Jiang G; Li Y; Ding Z; Zhang W; Zhou J; Ge J; Zou Y
    J Cardiovasc Pharmacol; 2015 Jun; 65(6):628-39. PubMed ID: 25806688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular function and regression of left ventricular hypertrophy in essential hypertension.
    Clement DL; De Buyzere M; Duprez D
    Am J Hypertens; 1993 Mar; 6(3 Pt 2):14S-19S. PubMed ID: 8466720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of left ventricular hypertrophy is a key goal of hypertension management.
    Zhang R; Crump J; Reisin E
    Curr Hypertens Rep; 2003 Aug; 5(4):301-8. PubMed ID: 12844464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of Antihypertensive Drugs on Regression of Left Ventricular Hypertrophy].
    Koziolova NA; Shatunova IM
    Kardiologiia; 2015; 55(6):88-97. PubMed ID: 26625525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis.
    Weinberg EO; Lee MA; Weigner M; Lindpaintner K; Bishop SP; Benedict CR; Ho KK; Douglas PS; Chafizadeh E; Lorell BH
    Circulation; 1997 Mar; 95(6):1592-600. PubMed ID: 9118530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
    Paull JR; Widdop RE
    J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options in minimizing left ventricular hypertrophy.
    Devereux RB
    Am Heart J; 2000 Jan; 139(1 Pt 2):S9-14. PubMed ID: 10618582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.